GO:0060336 negative regulation of type II interferon-mediated signaling pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0060336 describes any process that decreases the rate, frequency or extent of interferon-gamma-mediated signaling, a key brake on type II interferon immunity.
• The term is a biological_process child of negative regulation of signaling and is distinct from type I interferon regulation.
• Dysregulation of this process is linked to chronic inflammation, autoimmunity and impaired pathogen clearance.
• Key experimental approaches include knockout, point-mutation, knock-in and overexpression cell models combined with transcriptomics and proteomics.
• CRISPR screening and bioinformatics can identify novel negative regulators within this pathway.
• EDITGENE provides end-to-end CRISPR cell model and screening services to dissect GO:0060336 mechanisms.
Description
The Gene Ontology term GO:0060336, negative regulation of type II interferon-mediated signaling pathway, captures the cellular processes that dampen signaling downstream of interferon-gamma (IFN-gamma). Type II interferon signaling is central to host defense against intracellular pathogens and to immune surveillance, but its intensity and duration must be tightly controlled to avoid tissue damage and chronic inflammation. This term is therefore essential for researchers studying infection, autoimmunity and cancer immunology, because it defines the regulatory layer that sets the threshold for IFN-gamma responses. Experimental evidence shows that cytokines such as interleukin-1 beta can amplify antiviral responses, illustrating how interconnected cytokine networks modulate interferon signaling outcomes. Understanding GO:0060336 helps interpret how cells balance effective immunity with immune homeostasis.
negative regulation of type II interferon-mediated signaling pathway At A Glance
| GO ID | GO:0060336 |
|---|---|
| GO term | negative regulation of type II interferon-mediated signaling pathway |
| Ontology | biological_process |
| Synonym | negative regulation of interferon-gamma-mediated signaling pathway; negative regulation of gamma-interferon-mediated signaling pathway; negative regulation of immune interferon-mediated signaling pathway; negative regulation of type II IFN-mediated signaling pathway |
| Major function | Attenuation of IFN-gamma-induced signaling to prevent excessive immune activation |
| Biological context | Immune regulation, host-pathogen interaction, inflammation resolution |
| Related processes | Type II interferon-mediated signaling pathway (GO:0060333); regulation of cytokine signaling |
| Disease relevance | Autoimmunity, chronic inflammation, impaired pathogen clearance, cancer immune evasion |
What Is GO:0060336?
GO:0060336 is defined as any process that decreases the rate, frequency or extent of an interferon-gamma-mediated signaling pathway. In other words, it encompasses molecular events that attenuate the cellular response to IFN-gamma, including reduced receptor-proximal signaling, altered transcription factor activation, or increased expression of inhibitory proteins. This negative regulation ensures that IFN-gamma-driven gene programs are not overactivated, protecting tissues from excessive inflammation while preserving essential antimicrobial functions.
Why Is negative regulation of type II interferon-mediated signaling pathway Important in Cell Biology?
GO:0060336 is important because IFN-gamma signaling is a double-edged sword: it is required for macrophage activation and MHC upregulation, yet unchecked signaling drives immunopathology. Negative regulation of this pathway is therefore a critical determinant of disease outcome in infections, autoimmune conditions and tumors. For example, interleukin-1 beta has been shown to amplify interferon alpha-induced antiviral responses, highlighting how cytokine crosstalk can reshape interferon signaling strength. Researchers targeting GO:0060336 may uncover strategies to boost immunity where it is insufficient or to suppress it where it is harmful.
• Prevents tissue damage from sustained IFN-gamma-driven inflammation.
• Shapes the balance between pathogen clearance and immune pathology.
• Modulates macrophage and T cell effector functions.
• Influences autoimmune disease susceptibility and severity.
• Affects tumor immune surveillance and immunotherapy responses.
• Provides targets for host-directed therapies against intracellular pathogens.
• Helps explain inter-individual variability in interferon responses.
• Guides development of CRISPR models to dissect regulatory nodes.
• Supports biomarker discovery for inflammatory and infectious diseases.
• Connects cytokine crosstalk, such as IL-1 beta amplification of antiviral responses, to IFN-gamma regulation.
What Happens During negative regulation of type II interferon-mediated signaling pathway?
Initiation of IFN-gamma signaling and its negative feedback
In simple terms: When IFN-gamma binds its receptor, cells turn on antiviral genes, but they also start making brakes to stop the response from going too far.
IFN-gamma binding to its receptor triggers JAK-STAT signaling and transcription of interferon-stimulated genes. Negative regulation of this pathway begins with the induction of feedback inhibitors that reduce the rate or extent of signaling. Cytokine crosstalk can modulate this balance, as interleukin-1 beta has been shown to amplify interferon alpha-induced antiviral responses, indicating that inflammatory cytokines can influence interferon signaling outcomes.
Attenuation of receptor-proximal signaling
In simple terms: Cells can dial down the signal right at the receptor by increasing proteins that interfere with JAK-STAT activation.
Negative regulation often involves increased expression or activity of proteins that dephosphorylate or degrade signaling intermediates, thereby decreasing the frequency of active STAT complexes. This step is critical for limiting the duration of IFN-gamma responses. The precise molecular players vary by cell type, but the outcome is a reduced rate of IFN-gamma-mediated gene transcription.
Modulation of transcription factor activity
In simple terms: Even if the signal reaches the nucleus, cells can block the transcription factors that turn on IFN-gamma target genes.
Negative regulators can sequester or modify STAT1 and other transcription factors, preventing them from binding DNA or recruiting coactivators. This reduces the extent of IFN-gamma-mediated transcriptional programs. Such regulation is essential for resolving inflammation and avoiding chronic immune activation.
Integration with other cytokine networks
In simple terms: The brakes on IFN-gamma signaling do not work alone; they are influenced by other cytokines like IL-1 beta.
Interleukin-1 beta can amplify interferon alpha-induced antiviral responses, demonstrating that cytokine networks intersect to tune interferon signaling. This integration means that negative regulation of type II interferon signaling can be context-dependent, shaped by the broader inflammatory milieu. Understanding these interactions is key to predicting how cells respond to combined cytokine exposure.
Key Genes Involved in GO:0060336 negative regulation of type II interferon-mediated signaling pathway
The following genes and proteins are commonly studied in the context of negative regulation of type II interferon-mediated signaling, based on their roles in cytokine signaling and immune regulation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SOCS1 | Cytokine signaling suppressor | Negative regulator of JAK-STAT; frequently studied in IFN-gamma regulation |
| SOCS3 | Cytokine signaling suppressor | Modulates STAT activation downstream of IFN-gamma |
| PIAS1 | Protein inhibitor of activated STAT | Inhibits STAT1 DNA binding in IFN-gamma signaling |
| PTPN2 | Protein tyrosine phosphatase | Dephosphorylates JAKs and STATs to attenuate signaling |
| PTPN11 | Protein tyrosine phosphatase | Regulates JAK-STAT pathway activity |
| STAT1 | Signal transducer and transcription factor | Central mediator of IFN-gamma signaling and target of negative regulation |
| JAK1 | Janus kinase | Phosphorylates STAT1; regulated by phosphatases |
| JAK2 | Janus kinase | Partners with JAK1 in IFN-gamma receptor signaling |
| IFNGR1 | Interferon-gamma receptor subunit 1 | Receptor component whose turnover affects signaling strength |
| IFNGR2 | Interferon-gamma receptor subunit 2 | Receptor component involved in signal initiation |
| IL1B | Interleukin-1 beta | Amplifies interferon alpha-induced antiviral responses, showing cytokine crosstalk |
| IRF1 | Interferon regulatory factor 1 | Transcription factor induced by IFN-gamma; feedback regulated |
| NMI | N-myc and STAT interactor | Modulates STAT activity |
| CISH | Cytokine-inducible SH2-containing protein | Negative feedback regulator of cytokine signaling |
| USP18 | Ubiquitin-specific protease 18 | Regulates interferon signaling through ISG15 processing |
| TRIM21 | Tripartite motif-containing 21 | Regulates interferon signaling and immune responses |
How Is negative regulation of type II interferon-mediated signaling pathway Regulated?
Negative regulation of type II interferon-mediated signaling is itself regulated at multiple levels. Feedback loops involving SOCS proteins are induced by IFN-gamma and then shut down JAK-STAT activation. Cytokine crosstalk, such as interleukin-1 beta amplifying interferon alpha-induced antiviral responses, can indirectly influence the threshold for IFN-gamma regulation. Post-translational modifications, including phosphorylation, ubiquitination and SUMOylation, control the stability and activity of key signaling intermediates. Understanding these regulatory layers is essential for interpreting experimental data and for designing interventions that selectively tune IFN-gamma responses.
negative regulation of type II interferon-mediated signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SOCS1 | Autoimmunity, inflammation | Knockout and overexpression cell lines |
| PTPN2 | Inflammatory bowel disease, autoimmunity | Point-mutation knock-in models |
| STAT1 | Immunodeficiency, autoimmunity | Knock-in of patient mutations |
| IL1B | Inflammatory amplification of antiviral responses | Overexpression and knockout models |
| IFNGR1 | Mycobacterial susceptibility | Knockout and tagged knock-in |
Autoimmunity and chronic inflammation
Impaired negative regulation of IFN-gamma signaling can lead to sustained immune activation, contributing to autoimmune conditions such as lupus and rheumatoid arthritis. Excessive IFN-gamma activity promotes tissue damage and chronic inflammation. Studying GO:0060336 helps identify checkpoints that could be targeted to restore immune balance.
Infectious disease and pathogen clearance
Pathogens often exploit negative regulators of IFN-gamma signaling to evade immune responses. Conversely, insufficient negative regulation can cause immunopathology during infection. Cytokine crosstalk, such as IL-1 beta amplifying antiviral responses, may alter the balance between clearance and damage. Understanding these dynamics can inform host-directed therapies.
Cancer immunology
IFN-gamma signaling is critical for tumor immune surveillance, but tumors can upregulate negative regulators to escape immune attack. Modulating GO:0060336 may enhance immunotherapy efficacy. Research into this process can reveal biomarkers of response to immune checkpoint inhibitors.
From negative regulation of type II interferon-mediated signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate gene enhance IFN-gamma signaling? | Knockout cell line |
| Does a specific phosphorylation site regulate negative feedback? | Point-mutation knock-in |
| How does a disease-associated variant affect pathway output? | Knock-in of patient variant |
| Where does a regulator localize during signaling? | Tagged knock-in (e.g., GFP) |
| Does overexpression of a regulator suppress IFN-gamma responses? | Overexpression cell line |
| Which genes are essential for negative regulation? | CRISPR library screening |
How to Study the negative regulation of type II interferon-mediated signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Transcriptional changes | Measure IFN-gamma target gene expression |
| Phosphoproteomics | Phosphorylation of signaling proteins | Quantify JAK-STAT activation |
| Western blot | Protein levels and phosphorylation | Validate candidate regulators |
| Luciferase reporter | Pathway activity | Screen for modulators of IFN-gamma signaling |
| CRISPR knockout screen | Gene essentiality for pathway regulation | Identify novel negative regulators |
| Immunofluorescence | Subcellular localization | Track STAT1 nuclear translocation |
| Flow cytometry | Surface markers and cytokine production | Assess immune cell activation |
Transcriptomic profiling
RNA-seq can measure changes in IFN-gamma-stimulated gene expression upon perturbation of candidate regulators. This reveals the extent to which a gene contributes to negative regulation of the pathway.
Proteomic and phosphoproteomic analysis
Mass spectrometry-based proteomics can quantify phosphorylation events in JAK-STAT signaling, identifying how negative regulators alter signaling dynamics at the protein level.
Imaging and reporter assays
Live-cell imaging with fluorescent reporters of STAT1 nuclear translocation or IFN-gamma-responsive promoters can visualize the kinetics of negative regulation in real time.
CRISPR screening
Genome-wide CRISPR knockout or activation screens coupled with IFN-gamma-responsive reporters can identify novel negative regulators within GO:0060336.
How CRISPR Can Be Used to Study GO:0060336 negative regulation of type II interferon-mediated signaling pathway
Knockout
CRISPR knockout of candidate genes such as SOCS1 or PTPN2 can test whether they are required for negative regulation of IFN-gamma signaling. Loss of function typically leads to enhanced or prolonged STAT1 activation, which can be measured by reporter assays or transcriptomics.
Point Mutation
Introducing precise point mutations in genes like STAT1 or JAK1 can dissect the role of specific phosphorylation or interaction sites in negative regulation. This approach helps distinguish between signaling and regulatory functions.
Knock-in
Knock-in of disease-associated variants or tagged versions of regulators allows study of their impact on IFN-gamma signaling in a physiological context. Tagged knock-ins enable localization and interaction studies.
Overexpression
Overexpression of negative regulators such as SOCS3 or PIAS1 can suppress IFN-gamma responses, providing gain-of-function evidence. This is useful for validating sufficiency of a candidate regulator.
How EDITGENE Supports negative regulation of type II interferon-mediated signaling pathway Research
Researchers studying negative regulation of type II interferon-mediated signaling pathway-related genes often need to determine whether a candidate gene is causally involved in dampening IFN-gamma responses. EDITGENE provides the CRISPR tools and cell models to move from correlation to causation efficiently.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of type II interferon-mediated signaling pathway research.
Frequently Asked Questions About negative regulation of type II interferon-mediated signaling pathway
What is GO:0060336?
GO:0060336 is the Gene Ontology term for negative regulation of type II interferon-mediated signaling pathway, describing processes that decrease the rate, frequency or extent of IFN-gamma signaling.
What genes are involved in negative regulation of type II interferon-mediated signaling?
Key genes include SOCS1, SOCS3, PIAS1, PTPN2, PTPN11, STAT1, JAK1, JAK2, IFNGR1 and IFNGR2, among others.
Why is negative regulation of IFN-gamma signaling important?
It prevents excessive inflammation and tissue damage while allowing effective immune responses to pathogens.
How is type II interferon signaling negatively regulated?
Through feedback inhibitors like SOCS proteins, phosphatases such as PTPN2, and inhibitors of STAT DNA binding like PIAS1.
What diseases are linked to dysregulation of this pathway?
Autoimmune diseases, chronic inflammatory conditions, infectious diseases and cancer immune evasion.
What experimental models are used to study GO:0060336?
Knockout, point-mutation, knock-in and overexpression cell lines, as well as CRISPR library screens.
How can CRISPR help study negative regulation of IFN-gamma signaling?
CRISPR enables precise gene knockout, mutation or tagging to test causality of candidate regulators.
What is the role of IL-1 beta in interferon signaling?
IL-1 beta can amplify interferon alpha-induced antiviral responses, showing cytokine crosstalk that influences interferon signaling.
Which methods measure negative regulation of IFN-gamma signaling?
RNA-seq, phosphoproteomics, reporter assays, imaging and flow cytometry.
How does EDITGENE support research on GO:0060336?
EDITGENE offers CRISPR cell model generation, library screening and bioinformatics services tailored to this pathway.
Conclusion
GO:0060336 represents a critical control point in immunity, balancing the beneficial and harmful effects of IFN-gamma. Understanding its molecular players and regulatory logic is essential for developing therapies for autoimmune, infectious and malignant diseases. With advanced CRISPR tools and bioinformatics, researchers can now dissect this pathway with unprecedented precision.
References
- 1. Robichon K et al.. 2020. Identification of Interleukin1β as an Amplifier of Interferon alpha-induced Antiviral Responses.. PLoS Pathog 16(10):e1008461 PMID: 33002089
